Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948892 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL74396 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2200767 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL244740 | 0.82 | — | — | |
| SCHEMBL9550358 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1467609 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL254889 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21702260 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17803033 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL9237133 | 0.81 | TP53 (0.44) | TP53SMN1; SMN2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12084420-B2 | Indoline compounds for inhibiting KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4392407-A1 | SPIRO INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118103352-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023125935-A1 | BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125935-A1 | BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023028564-A1 | SPIRO INDOLINE INHIBITORS OF KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | TP53 99/4885SMN1; SMN2 2366/4885CHRNB2 2657/4885 |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | TP53 176/4885SMN1; SMN2 331/4885CHRNB2 37/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TP53 53/4885SMN1; SMN2 4705/4885CHRNB2 4868/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | TP53 99/4885SMN1; SMN2 2366/4885CHRNB2 2657/4885 |
| US-12084420-B2 | Indoline compounds for inhibiting KIF18A | KIF18A, KIF18B, KIF2C | TP53 105/4885SMN1; SMN2 2361/4885CHRNB2 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.